A Study of a Novel Investigational Drug in Rheumatoid Arthritis Patients (MK-0873-012)(COMPLETED)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 2

Conditions: Rheumatoid Arthritis

Treatments: Drug: MK-0873; Drug: Comparator: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00132769

2005_029 (Other Identifier)

0873-012

Details and patient eligibility

About

This study will look at whether this new drug is effective in the treatment of rheumatoid arthritis, and at whether it is safe and well-tolerated by participants with the disease.

Enrollment: 106 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Rheumatoid arthritis, according to the American College of Rheumatology criteria, with active disease despite current medications
• Other criteria also apply

Exclusion criteria

• Other major illnesses
• Past history of certain other disorders
• Certain prohibited medications

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

106 participants in 2 patient groups, including a placebo group

MK-0873

Experimental group

Description:

MK-0873 1.25 mg twice daily for 12 weeks

Treatment:

Drug: MK-0873

Placebo

Placebo Comparator group

Description:

Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks

Treatment:

Drug: Comparator: Placebo